Back to Search
Start Over
A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients.
- Source :
-
International journal of cardiology [Int J Cardiol] 2016 Oct 15; Vol. 221, pp. 60-74. Date of Electronic Publication: 2016 Jun 24. - Publication Year :
- 2016
-
Abstract
- The objective of the present study was to systematically review the clinical and economic outcomes of olmesartan as monotherapy or in combination with other antihypertensive agents in the treatment of hypertension. A literature search was performed using PubMed and the Cochrane library until December 2015, with no limit on publication date. Eligible studies were selected using predetermined inclusion and exclusion criteria, limiting articles to those published in the English language. Background information of the study, participants' characteristics and study outcomes were collected. Meta-analysis of data was not performed. Fifty-five studies were included, of which fifty investigated the clinical efficacy of olmesartan and five the cost-effectiveness of olmesartan. In general results from clinical trials evaluating the efficacy of olmesartan as monotherapy and as combination therapy demonstrated that olmesartan provided better antihypertensive blood pressure-lowering efficacy and was generally well tolerated compared with other antihypertensive agents. Results from economic evaluations indicated that olmesartan may be more cost-effective than other ARBs such as losartan, valsartan, irbesartan and candesartan, having the potential of decreasing the overall medical costs of care for patients with hypertension. Evidence from the present systematic review confirms the antihypertensive efficacy and good safety profile of olmesartan both as monotherapy and as combination therapy. Olmesartan was also found to be cost-effective compared with other ARBs, though this area has yet relatively poor evidence and needs to further be explored.<br /> (Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.)
- Subjects :
- Angiotensin II Type 1 Receptor Blockers economics
Angiotensin II Type 1 Receptor Blockers pharmacology
Antihypertensive Agents economics
Antihypertensive Agents pharmacology
Cost-Benefit Analysis
Humans
Treatment Outcome
Hypertension drug therapy
Hypertension economics
Imidazoles economics
Imidazoles pharmacology
Tetrazoles economics
Tetrazoles pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1874-1754
- Volume :
- 221
- Database :
- MEDLINE
- Journal :
- International journal of cardiology
- Publication Type :
- Academic Journal
- Accession number :
- 27404671
- Full Text :
- https://doi.org/10.1016/j.ijcard.2016.06.115